Expert Perspectives on Diagnosis, Management, and Emerging Therapies in Low-Grade Serous Ovarian Cancer - Episode 3
Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC
Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.
Summary:
RAMP 201, updated at ASCO 2023, is an exciting trial utilizing two oral agents for the treatment of low-grade serous ovarian cancer (LGSC). Avutometinib, a RAF/MEK dual inhibitor, and defactinib, an inhibitor addressing the FAK pathway, create a triple blockade strategy. Clinical benefit was observed in both cohorts of the original study, with avutometinib as a single agent and in combination with defactinib. Notably, the combination demonstrated a higher response rate compared to the single-agent arm.
The plan is to move forward with this combination approach for all patients, irrespective of KRAS mutation status. The design of the confirmatory phase three trial, RAMP 301 or GOG 3097, has been outlined. It will evaluate the combination of avutometinib and defactinib against standard care treatment in patients with current low-grade serous ovarian cancer. Standard care treatment allows for hormonal therapy and cytotoxic options, providing a range of choices for patient management.
Emphasizing the importance of clinical research access, David M. O’Malley, MD, urges practitioners to seek trials for their patients, even if not available at their site. Access to these agents through clinical research is crucial for advancing knowledge and obtaining approvals for patient benefit.
Considerations for LGSC include pathology review, evaluating the role of surgery in both primary and recurrent settings for optimal site reduction, and a multidisciplinary approach involving surgical oncologists, infertility specialists, and others. The primary emphasis is on ensuring all patients undergo tissue testing for actionable mutations and prioritizing access to clinical trials for optimal patient outcomes. The progress in LGSC is attributed to global research efforts and collaborative partnerships aimed at obtaining approval for these promising agents through clinical trials.
Summary is AI-generated and reviewed by OncLive editorial staff.
Related Content:
